Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.

International journal of physiology, pathophysiology and pharmacology Pub Date : 2019-08-15 eCollection Date: 2019-01-01
Aryan Rafiee Zadeh, Keyvan Ghadimi, Akram Ataei, Mozhde Askari, Neda Sheikhinia, Nooshin Tavoosi, Masih Falahatian
{"title":"Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.","authors":"Aryan Rafiee Zadeh, Keyvan Ghadimi, Akram Ataei, Mozhde Askari, Neda Sheikhinia, Nooshin Tavoosi, Masih Falahatian","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple Sclerosis (MS) is an autoimmune, inflammatory disease of the central nervous system (CNS) mostly affecting young adults. The exact mechanism and pathogenesis of MS remain still undiscovered but there have been useful treatments with different efficacy rates. Most of these therapies are divided into the first line, second line and third line, impact on the immune system and immune cells. These drugs are approved to be useful in MS, but like any other therapies, adverse effects (AE) are associated with these drugs. In this review, we continue the survey over mechanisms of actions and AEs of MS drugs. Physicians must be aware of such AEs and complications to choose the best drug for each patient.</p>","PeriodicalId":94056,"journal":{"name":"International journal of physiology, pathophysiology and pharmacology","volume":"11 4","pages":"105-114"},"PeriodicalIF":0.0000,"publicationDate":"2019-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737425/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of physiology, pathophysiology and pharmacology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Multiple Sclerosis (MS) is an autoimmune, inflammatory disease of the central nervous system (CNS) mostly affecting young adults. The exact mechanism and pathogenesis of MS remain still undiscovered but there have been useful treatments with different efficacy rates. Most of these therapies are divided into the first line, second line and third line, impact on the immune system and immune cells. These drugs are approved to be useful in MS, but like any other therapies, adverse effects (AE) are associated with these drugs. In this review, we continue the survey over mechanisms of actions and AEs of MS drugs. Physicians must be aware of such AEs and complications to choose the best drug for each patient.

多发性硬化症药物的机制和不良反应:综述文章。第 2 部分。
多发性硬化症(MS)是一种自身免疫性中枢神经系统(CNS)炎症性疾病,多发于青壮年。多发性硬化症的确切机制和发病机理仍未被发现,但已经有了不同疗效的有效治疗方法。这些疗法大多分为一线、二线和三线,对免疫系统和免疫细胞产生影响。这些药物已被批准用于多发性硬化症的治疗,但与其他疗法一样,这些药物也会产生不良反应(AE)。在本综述中,我们将继续探讨多发性硬化症药物的作用机制和不良反应。医生必须了解这些不良反应和并发症,以便为每位患者选择最佳药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信